# Pacira BioSciences, Inc. Common Stock (PCRX)

> Today's trading snapshot for PCRX: day range, open, previous close, volume and market cap.

Canonical: https://massive.com/quote/pcrx
Data as of: 2026-11-17T00:30:04.673Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

As of 7:30:04 PM EST on Nov 16, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Pacira BioSciences, Inc. Common Stock (PCRX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +0.05% |
| 1W | +0.05% |
| 1M | +0.39% |
| YTD | +40.96% |
| 1Y | +49.94% |
| 52-wk range | $18.80 – $36.67 |

From daily closes through Nov 16, 2026.

## Key statistics

Today's trading snapshot for PCRX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | — |
| Open | — |
| Prev close | $36.48 |
| Volume | 0 |
| Market cap | $1.46B |
| Shares out | 40.09M |

## Valuation and profitability ratios

Valuation and profitability ratios for Pacira BioSciences, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | 38.59 |
| P/S | 1.96 |
| P/B | 2.04 |
| P/FCF | 8.62 |
| ROE | 5.3% |
| ROA | 3.1% |
| Debt/Equity | 0.41 |
| Div yield | 0.00% |

As of Nov 16, 2026

## Insider trading

[Pacira BioSciences, Inc. Common Stock (PCRX) insider trading](https://massive.com/quote/pcrx/insider-trading.md): open-market Form 4 buys and sells by Pacira BioSciences, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Pacira BioSciences, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 17, 2026 · Debt retirement
  “On November 17, 2026, $96,392.50, which represented all amounts outstanding under the Credit Agreement, was repaid in full, the Credit Agreement and all commitments thereunder were terminated and all liens securing obligations under the Credit Agreement will be released.”
- Nov 12, 2026 · Material charge or gain
  “In June 2025, the U.S. District Court for the District of Nevada issued judgment in favor of the Company declaring that RDF was required to repay Pacira $23.1 million in royalties on EXPAREL sales that were previously paid under protest. The District Court also awarded Pacira an additional interest payment of $5.2 million in statutory interest on the royalties paid under protest.”
- Nov 5, 2026 · Tender offer
  “On October 30, 2026, Purchaser commenced a tender offer (the "Offer") to purchase all of the issued and outstanding shares of common stock ... of the Company for $36.50 per Share, in cash, net of applicable withholding taxes and without interest.”
- Oct 8, 2026 · Acquisition agreement
  “Pursuant to the Merger Agreement, Purchaser will commence a cash tender offer to acquire all of the outstanding shares of common stock of the Company... at an offer price of $36.50 per Share in cash.”
- Jun 30, 2026 · Divestiture agreement
  “On June 28, 2026, Pacira BioSciences, Inc. (the "Company") and Pacira CryoTech, Inc., the Company's wholly owned subsidiary (the "Subsidiary"), entered into a Stock and Asset Purchase Agreement (the "Purchase Agreement") with Zimmer, Inc. (the "Purchaser"), a subsidiary of Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"). Pursuant to the Purchase Agreement, the Company has agreed to divest to the Purchaser (i) all of the issued and outstanding capital stock of the Subsidiary and (ii) certain assets and liabilities of the Company and certain of its subsidiaries relating to the Company's handheld cryoanalgesia devices and related products, including iovera®° (the "Transaction") for up to $140.0 million, including an upfront payment of $70.0 million.”

## PCRX short interest

How heavily PCRX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 3.9 |
| Short interest | 3.35M |
| Avg volume | 855.6K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## PCRX news

The latest news and headlines about Pacira BioSciences, Inc. Common Stock (PCRX).

- [Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?](https://www.zacks.com/stock/news/3020638/harrow-hrow-expected-to-beat-earnings-estimates-should-you-buy?cid=CS-ZC-FT-fundamental_analysis|yseop_template_9-3020638) · Zacks Investment Research · Nov 2, 2026 · positive sentiment
- [Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio](https://www.zacks.com/stock/news/3003812/viatris-to-buy-pacira-for-1-65b-to-expand-non-opioid-pain-portfolio?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-3003812) · Zacks Investment Research · Oct 9, 2026 · positive sentiment
- [Why Pacira BioSciences Skyrocketed Today](https://www.fool.com/investing/2026/10/08/why-pacira-biosciences-skyrocketed-today/?source=iedfolrf0000001) · The Motley Fool · Oct 8, 2026 · positive sentiment
- [PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal](https://www.zacks.com/stock/news/3001030/pcrx-expands-exparel-commercial-reach-in-europe-through-molteni-deal?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-3001030) · Zacks Investment Research · Oct 6, 2026 · positive sentiment
- [Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?](https://www.zacks.com/stock/news/2984553/pacira-pcrx-up-6-9-since-last-earnings-report-can-it-continue?cid=CS-ZC-FT-realtime_blog-2984553) · Zacks Investment Research · Sep 3, 2026 · neutral sentiment

## About Pacira BioSciences, Inc. Common Stock

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 829 |
| Listed | Feb 3, 2011 |

[Company website](https://www.pacira.com)

## FAQ

### What is the Pacira BioSciences, Inc. Common Stock (PCRX) stock price today?

Massive provides real-time and historical Pacira BioSciences, Inc. Common Stock (PCRX) quotes via REST API, WebSocket and MCP.

### What is Pacira BioSciences, Inc. Common Stock?

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients.

### What is the short interest in PCRX?

As of Oct 30, 2026, PCRX has 3.35M shares short and 3.9 days to cover.

### What exchange is PCRX listed on?

Pacira BioSciences, Inc. Common Stock (PCRX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time PCRX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=PCRX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Pacira BioSciences, Inc. Common Stock (PCRX) insider trading](https://massive.com/quote/pcrx/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
